European Commission Approves XEPLION(R) for Treatment of Schizophrenia

BEERSE, Belgium, March 9, 2011 - Janssen-Cilag International NV today announced that XEPLION(R)
(paliperidone palmitate), a once monthly, long-acting injectable,
antipsychotic, has received approval from the European Commission for the
treatment of schizophrenia.

Schizophrenia is relatively common and the prevalence is similar around
the world. The lifetime risk for schizophrenia is estimated to be one person
in 100, and appears to be the same for men and women up to age 60 years.[1]
Schizophrenia is a devastating mental illness for both the patients and their
families and friends, as it seriously impairs a person's ability to think
clearly, relate to others and to function properly in society. While there is
no cure, many people with the illness respond well to antipsychotic
medicines, the mainstay of treatment for schizophrenia.

However, further relapses can have a terrible effect on the lives of
patients with schizophrenia and their families. Frequent relapses and
hospitalisation can increase the person's isolation and make it even more
difficult for them to find and keep a job.[2],[3],[4],[5],[6] Prevention of
future relapses is a crucial goal of therapy and patients who stay on
continual treatment are more likely to achieve optimal outcomes.[7],[8]

Patients with schizophrenia who are non-adherent to medication are up to
five times more likely to relapse than those patients who are adherent and
continue on medication, significantly increasing the likelihood of
hospitalisation,[9] which in turn increases the overall cost of care.

"Relapse can have a devastating effect on patients with schizophrenia and
more needs to be done to actively improve adherence to medication if we are
to break the cycle of decline," said Professor Fernando Cañas, Head of
Department of Psychiatry, Hospital Dr Rodríguez Lafora, Madrid, Spain.*
"Long-acting injectable antipsychotics such as XEPLION(R) can help patients
to maintain continual treatment, thereby reducing the likelihood of relapse.
This is imperative not only to reduce the suffering and cost burden
associated with relapse in schizophrenia, but to improve the future outlook
and overall quality of life for these patients."

The Clinical Data

The efficacy of XEPLION(R) was established in four double-blind placebo
controlled studies in patients with an acute exacerbation of schizophrenia
and a longer-term double blind relapse prevention/maintenance study.[10],[11]
,[12],[13],[14] XEPLION(R) was superior to placebo in improving symptoms of
schizophrenia as measured by the change in the positive and negative syndrome
scale (PANSS) total scores from baseline to endpoint in the acute treatment
trials and significantly delayed time to relapse vs. placebo in the
longer-term maintenance study.[15]

The most recent acute symptom control study was a multi-centre,
randomised, placebo-controlled, double-blind, parallel-group study (n=636).
[10] All patients received a dose of 150 mg eq. on Day 1 in the deltoid
muscle. From Day 8 and monthly thereafter, patients were assigned to one of
three fixed doses of XEPLION(R) (25, 100 and 150 mg eq) administered into
either the deltoid or gluteal muscle for a period of 13 weeks. All three
doses of XEPLION(R) were superior to placebo in improving the PANSS total
score at endpoint (the primary measure of efficacy). The results support
efficacy across the entire duration of treatment, with onset of efficacy and
significant improvement in PANSS compared to placebo observed from day 8 in
some patients. The results of the other studies also yielded significant
results in favour of XEPLION(R).[13]

The efficacy of XEPLION(R) in maintaining symptomatic control and
delaying relapse in schizophrenia was established in a longer-term,
randomised, double-blind, placebo-controlled, flexible-dose study involving
849 patients with schizophrenia.[14] A total of 410 stabilised patients were
randomised to either XEPLION(R) or to placebo until they experienced a
relapse of schizophrenia symptoms in the variable length double-blind phase
of the study. The trial was stopped early for efficacy reasons as a
significantly longer time to relapse (p < 0.0001) was seen in patients
treated with XEPLION(R) compared to placebo. During the double-blind phase of
the study, fewer patients treated with XEPLION(R) experienced a relapse (10%
[n=15/156]) compared with those in the placebo group (34% [n=53/156]).[14]
The final analyses confirmed the results of the interim analysis.

"XEPLION(R) provides healthcare professionals with the opportunity to
rethink their overall approach to how they treat schizophrenia by using
long-acting therapies," says Dr Christophe Tessier**, Medical Affairs
Director, Psychiatry, Janssen EMEA. "The approval of XEPLION(R) demonstrates
Janssen's ongoing commitment to providing novel therapies for schizophrenia.
As a once monthly injection, XEPLION(R) can help healthcare professionals
address the issue of non-adherence to medication thus ensuring symptom
control and allowing patients to focus on shaping their lives."

About XEPLION(R) (paliperidone palmitate)

XEPLION(R) is a once-monthly, long-acting, injectable, atypical
antipsychotic. XEPLION(R) will be available in Europe in milligrams (mg) of
paliperidone palmitate in dose strengths of 25***, 50, 75, 100 and 150 mg.
After the first two initiation injections, XEPLION(R) can be administered in
either the deltoid (arm) or gluteal (buttock) muscle.

The approved indication is:

XEPLION(R) is indicated for maintenance treatment of
schizophrenia in adult patients stabilised with paliperidone or risperidone.
In selected adult patients with schizophrenia and previous responsiveness to
oral paliperidone or risperidone, XEPLION(R) may be used without prior
stabilisation with oral treatment if psychotic symptoms are mild to moderate
and a long-acting injectable treatment is needed.

Tolerability

In the clinical development programme XEPLION(R) was generally
well tolerated with no new safety signals identified in comparison to oral
paliperidone ER with the exception of local injection site reactions.[10-14]
The most frequently reported adverse effects during the clinical trials were
insomnia (difficulty sleeping), headache, weight increase, injection site
reactions, agitation, somnolence, akathisia (restlessness), nausea,
constipation, dizziness, tremor, vomiting, upper respiratory tract infection
(infection of the nose, throat, or chest), diarrhoea, and tachycardia (rapid
heart rate).[15]

XEPLION(R) was developed utilising Elan Drug Technologies' proprietary
NanoCrystal(R) Technology. Using this technology increases the rate of
dissolution and enables the formulation of an aqueous suspension for
once-monthly intramuscular administration.

About Schizophrenia

Schizophrenia is a chronic, severe and disabling brain disorder that
seriously impairs a person's ability to think clearly, relate to others and
to function productively in society. The consequences of the disorder include
difficulties in thought processes leading to hallucinations, delusions,
disordered thinking and unusual speech or behaviour.

About Janssen

Janssen-Cilag International NV is one of the Janssen Pharmaceutical
Companies of Johnson & Johnson, which are dedicated to addressing and solving
the most important unmet medical needs of our time, including oncology (e.g.
multiple myeloma and prostate cancer), immunology (e.g. psoriasis),
neuroscience (e.g. schizophrenia, dementia and pain), infectious disease
(e.g. HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and
metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we
develop sustainable, integrated healthcare solutions by working side-by-side
with healthcare stakeholders, based on partnerships of trust and
transparency. More information can be found at www.janssen-emea.com

(This press release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements are
based on current expectations of future events. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual
results could vary materially from Janssen-Cilag International NV's and/or
Johnson & Johnson's expectations and projections. Risks and uncertainties
include general industry conditions and competition; economic conditions,
such as interest rate and currency exchange rate fluctuations; technological
advances and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approvals; domestic and
foreign health care reforms and governmental laws and regulations; and trends
toward health care cost containment. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of Johnson
& Johnson's Annual Report on Form 10-K for the fiscal year ended January 2,
2011. Copies of this Form 10-K, as well as subsequent filings, are available
online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
Neither Janssen-Cilag International NV nor Johnson & Johnson undertake to
update any forward-looking statements as a result of new information or
future events or developments.)

Notes

* Professor Fernando Cañas has at times been a paid consultant of
Janssen.

** Dr Christophe Tessier is a full time employee of Janssen, EMEA.

*** 25mg will not be available in all countries.

References

———————————

[1] Lehman A et al. Practice guideline for the treatment of patients with
schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56

[2] Thornicroft G, Brohan E, Rose D, et al for the INDIGO Study Group.
Lancet.2009;373(9661):408-15.

[3] Marwaha S, Johnson S, Bebbington P, et al. Br J Psychiatry.
2007;191:30-7.

[4] Marwaha S, Johnson S. Soc Psychiatry Psychiatr Epidemiol.
2004;39(5):337-49.

[5] Nithsdale V, Davies J, Croucher P. J Occup Rehabil. 2008;18(2
):175-82.

[6] Rosenheck R, Leslie D, Keefe R, et al; CATIE Study Investigators
Group. Am J Psychiatry. 2006;163(3):411-417.

[7] Masand PS, Roca M, Turner MS et al. Partial adherence to
antipsychotic medication impacts course of illness in patients with
schizophrenia: a review. Prim Care Companion J Clin Psychiatry.
2009;11(4):147-54.

[8] Peuskens J, Olivares JM, Pecenak J et al. Treatment retention with
risperidone long-acting injection: 24-month results from the Electronic
Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr
Med Res Opin 2010;26:501-509

[9] Kane JM. Treatment adherence and long-term outcomes. CNS Spectrums.
2007: 12 (10 Suppl 17), 21-26.

[10] Pandina et al. A Randomised, Placebo Controlled Study to Assess the
Efficacy and Safety of 3 Doses of paliperidone Palmitate in Adults With
Acutely Exacerbated Schizophrenia. J Clin Psychopharmacol. 2010; 30: 235-244.

[11] Nasrallah HA et al. A controlled evidence based trial of
paliperidone palmitate, a long-acting injectable antipsychotic, in
schizophrenia. Neuropsychopharmacology. 2010; 35(10): 207-282.

[12] Gopal S et al. Efficacy and safety of paliperidone palmitate in
adult patients with acutely symptomatic schizophrenia: a randomized,
double-blind, placebo-controlled, dose-response study. Int Clin
Psychopharmacology. 2010; 25(5): 24756

[13] Kramer et al. Paliperidone palmitate, a potential long-acting
treatment for patients with schizophrenia. Results of a randomized,
double-blind, placebo-controlled efficacy and safety study. Int J
Neuropsychopharmacology. 2009; 27: p113.

[14] Hough D et al. Paliperidone palmitate maintenance treatment in
delaying the time to relapse in patients with schizophrenia: A randomized,
double-blind placebo-controlled study. Schizophrenia Research. 2010; 116
(23): 107-117.

[15] Xeplion(R) SmPC 2011

For further information please contact: Sue Silk, Janssen EMEA, Tel: +44-1494-553955, Email: ssilk at its.jnj.com . Johnson & Johnson Investor Relations: Stan Panasewicz: +1-732-524-2524, Louise Mehrotra: +1-732-524-6491. Joanna Smith, Resolute Communications, Tel: +44-207-357-8187, Email: joanna.smith at resolutecommunications.com